Tucidinostat (chidamide)
Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.
Overview
Chipscreen Biosciences' chidamide was approved by the CFDA in December 2014 for relapsed or refractory peripheral T-cell lymphoma, the first China-origin small molecule in a new chemical class and the first oral subtype-selective HDAC inhibitor approved anywhere. The ACE trial (Lancet Oncology 2019) added HR-positive advanced breast cancer with exemestane after endocrine therapy, approved in 2019. Licensed to HUYA Bioscience as HBI-8000, it was approved in Japan in 2021 for adult T-cell leukaemia-lymphoma and is being tested with PD-1 antibodies in melanoma.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2014 | Relapsed or refractory peripheral T-cell lymphoma |
| China | 2019 | HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE) |
| Japan | 2021 | Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tucidinostat" OR ABSTRACT:"Tucidinostat" OR TITLE:"chidamide" OR ABSTRACT:"chidamide" OR TITLE:"Epidaza" OR ABSTRACT:"Epidaza" OR TITLE:"HBI-8000" OR ABSTRACT:"HBI-8000" OR TITLE:"CS055" OR ABSTRACT:"CS055" OR TITLE:"Chidamide" OR ABSTRACT:"Chidamide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tucidinostat (chidamide), not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductSugemalimab
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag china.
- ProductDalpiciclib
Shares HR-positive / HER2-negative breast cancer and the tag china.
- TrialDAWNA-1
Shares HR-positive / HER2-negative breast cancer and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares HR-positive / HER2-negative breast cancer and the tag china.
- ProductBelinostat
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- ProductRomidepsin
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- CompanyPrelude Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), HR-positive / HER2-negative breast cancer.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), HR-positive / HER2-negative breast cancer.